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Multiple system atrophy (MSA) is a sporadic, adult‐onset α‐synucleinopathy with a rapidly progressive disease course and widespread neurodegeneration.[1](#mds27669-bib-0001){ref-type="ref"} Clinicopathological studies identified 2 motor phenotypes---a parkinsonian variant (MSA‐P) and a cerebellar variant (MSA‐C) with predominant degeneration in striatonigral and olivopontocerebellar nuclei and their projections, respectively.[2](#mds27669-bib-0002){ref-type="ref"} The key pathological findings include demonstration of neuronal cell loss and the appearance of widespread oligodendroglial α‐synuclein positive inclusions.[3](#mds27669-bib-0003){ref-type="ref"} Neuropathological studies revealed considerable variability in the severity and regional distribution of neuropathological changes between individual patients. In 2 series, 42% to 49% of MSA cases showed equally severe striatonigral degeneration (SND) and olivopontocerebellar atrophy (OPCA), whereas predominant SND or OPCA was seen in 34% and 17% of cases, respectively.[4](#mds27669-bib-0004){ref-type="ref"} Those studies failed to find a correlation between the severity of clinical symptoms and the extent of neuronal degeneration or the intracellular load of glial cytoplasmatic inclusions. Based on these observations, MR volumetry will likely require measures of both SND and OPCA to adequately capture MSA pathology. Within the olivopontocerebellar system, the middle cerebellar peduncle (MCP) was shown to be one of the most prominently affected brain regions, and imaging studies in patients with MSA and PD have shown that MSA is associated with a greater pontine and MCP atrophy compared with PD.[5](#mds27669-bib-0005){ref-type="ref"}, [6](#mds27669-bib-0006){ref-type="ref"}, [7](#mds27669-bib-0007){ref-type="ref"}, [8](#mds27669-bib-0008){ref-type="ref"}, [9](#mds27669-bib-0009){ref-type="ref"}, [10](#mds27669-bib-0010){ref-type="ref"}, [11](#mds27669-bib-0011){ref-type="ref"}, [12](#mds27669-bib-0012){ref-type="ref"}

So far, diagnostic imaging studies in MSA have focused on the validation of either 2‐dimensional distance measures, calculation of indices, or whole‐brain voxel‐based analysis to identify disease characteristic patterns of atrophy.[13](#mds27669-bib-0013){ref-type="ref"}, [14](#mds27669-bib-0014){ref-type="ref"} Although such approaches have the potential to reveal disease‐related signal alterations, efforts to rank patterns of atrophy by their severity at the single‐subject level and hence disentangle the dimensions' "signal distribution" and "signal quantity" are sparse.[15](#mds27669-bib-0015){ref-type="ref"}, [16](#mds27669-bib-0016){ref-type="ref"} Advances in MRI postprocessing algorithms including automated compartmentalization of the brain into multiple anatomic regions, volume calculation, and *z* transformation have provided an opportunity to localize and grade disease‐specific brain atrophy patterns in relation to age‐ and sex‐matched healthy control cohorts.[17](#mds27669-bib-0017){ref-type="ref"}, [18](#mds27669-bib-0018){ref-type="ref"} Recently, such an approach was shown to reliably differentiate progressive supranuclear palsy Richardson type and MSA‐P from Parkinson\'s disease.[19](#mds27669-bib-0019){ref-type="ref"} However, there is still room for improvement because current atlases lack probabilistic information on infratentorial brain structures that are relevant to MSA neuropathology. In particular, cerebellar volume, the MCP width, increased apparent diffusion coefficient within the MCP as well as the cerebellar hemispheres, and pons atrophy were shown to improve diagnostic accuracy in the differential diagnosis of MSA.[9](#mds27669-bib-0009){ref-type="ref"}, [20](#mds27669-bib-0020){ref-type="ref"}, [21](#mds27669-bib-0021){ref-type="ref"}, [22](#mds27669-bib-0022){ref-type="ref"}

In the present study, we sought to further refine the currently available FreeSurfer‐based subcortical segmentation atlas by adding probabilistic information on the location of the MCP. The morphometric profile was determined in patients with clinically defined MSA‐P or MSA‐C to evaluate the relative contribution of MCP measurements to diagnostic accuracy and to estimate the added diagnostic yield of MCP measurements for the differential diagnosis of MSA and PD.

Materials and Methods {#mds27669-sec-0006}
=====================

*Participants* {#mds27669-sec-0007}
--------------

Forty‐eight healthy individuals (HCs) without evidence of any neurological disorder on careful clinical examination underwent conventional 3 T MRI and were used for the development of the novel atlas. Twenty‐six of these 48 healthy individuals were selected by investigator‐independent case‐control matching (see below) as a sex‐ and age‐matched healthy control group in our cross‐sectional study. MSA and PD patients were identified from the MRI database of the Movement Disorders outpatient clinic of the Department of Neurology at the Medical University of Innsbruck. Inclusion criteria were defined as: (1) a clinical diagnosis of probable MSA (either parkinsonian or cerebellar variant) or PD at the last visit according to consensus operational criteria,[23](#mds27669-bib-0023){ref-type="ref"}, [24](#mds27669-bib-0024){ref-type="ref"} and (2) a clinical follow‐up of at least 24 months. Exclusion criteria were dementia according to the Diagnostic and Statistical Manual IV criteria, white‐matter lesions grades 2 and 3, vascular or space‐occupying lesions within the cerebrum, or motion artifacts on MRI.

The study was approved by the Ethics Committee of the Medical University of Innsbruck.

*MR Sequence* {#mds27669-sec-0008}
-------------

All MRI measurements were performed on a 3.0 Tesla whole‐body MR scanner (Magnetom Verio, Siemens, Erlangen, Germany) equipped with a 12‐channel head coil. All participants underwent the same MRI protocol, including whole‐brain T1‐weighted, fluid‐attenuated inversion‐recovery, T2‐, and proton density‐weighted as well as diffusion tensor imaging. The MRI parameters for the coronal T1‐weighted 3‐dimensional (3‐D) magnetization‐prepared rapid gradient echo were TR, 1800 milliseconds; TE, 2.18 milliseconds; inversion time, 900 milliseconds; slice thickness, 1.2 mm; matrix, 256 × 204 pixels; number of excitations, 1; flip angle, 9°; field of view, 220 × 165 mm.

Segmentation of subcortical regions from T1‐weighted 3‐D structural MRI data and estimation of structure volumes were performed using the FreeSurfer tool kit (version 6.0, available at <http://surfer.nmr.mgh.harvard.edu/>). The procedure automatically segments and labels brain structures based on (1) the prior probabilities of anatomical classes throughout an atlas space, (2) the prior probability obtained from frequency histograms within the atlas space providing the likelihood that a given anatomical class occurs at a given atlas location, and (3) the modeling of local spatial relationships between labeled structures as anisotropic nonstationary Markov random fields.[18](#mds27669-bib-0018){ref-type="ref"} The processing of T1‐weighted 3‐D structural MRIs included correction of motion artifacts, removal of nonbrain tissue, transformation into the Talairach reference space, segmentation of the subcortical white matter and deep gray‐matter volumetric structures, intensity normalization, tessellation of the gray matter, white‐matter boundary, automated topology correction, and surface deformation following intensity gradients.[17](#mds27669-bib-0017){ref-type="ref"}, [18](#mds27669-bib-0018){ref-type="ref"}, [25](#mds27669-bib-0025){ref-type="ref"}, [26](#mds27669-bib-0026){ref-type="ref"}, [27](#mds27669-bib-0027){ref-type="ref"} The procedure generated the intracranial volume as well as the volumes of the putamen, caudate, globus pallidum, thalamus, hippocampus, amygdala, brain stem, cerebellar white and gray matter, MCP, and the third and fourth ventricles. The preprocessing steps were visually inspected to ensure that no misalignment of brain structures had occurred. All MRI scans were included in the study. All imaging data were processed on an HP DL360p server with a total of 48 CPUs. Time needed to perform the automated volume calculation was approximately 8 hours for each subject, and 48 subjects were processed in parallel.

*Atlas Development* {#mds27669-sec-0009}
-------------------

The MCP was identified in all subjects by exploiting a validated probabilistic 3‐D atlas of cerebellar white‐matter structure.[28](#mds27669-bib-0028){ref-type="ref"} The observer independently segmented brain volume of the MCP was transformed to the individual subject\'s space using the deformation parameters obtained from the normalization procedure into Montreal Neurological Institute space by the software package SPM12 in Matlab 9.2. A subject\'s MCP volumes were reviewed and manually corrected if required in native space. Subsequently, the individual MCP maps were integrated into the default subcortical segmentation atlas as described previously.[18](#mds27669-bib-0018){ref-type="ref"} Three‐dimensional models of automatically segmented MCP in PD and MSA‐C are presented in the online supplement (Supplementary [Fig. 1](#mds27669-supitem-0001){ref-type="supplementary-material"})

*Statistical Analysis* {#mds27669-sec-0010}
----------------------

Data analysis was performed using SPSS 24.0 and STATA 14.2. Case‐control matching was performed through the SPSS extension FUZZY with a fuzz of 0 for gender and 1.5 years for age.

Demographic data are presented as frequencies, means ± standard deviations, or median (interquartile range) according to data distribution. Gaussian distribution was confirmed by visual analysis of the Q‐Q plots and the Kolmogorov‐Smirnov test. Group differences of normally distributed data were analyzed by parametric tests (analysis of variance \[ANOVA\] or Student *t* test as applicable), non‐Gaussian distributed variables by nonparametric tests (Kruskal‐Wallis 1‐way ANOVA by ranks or Mann‐Whitney *U* test as applicable). Distributional differences were determined by the Pearson\'s chi‐square test for independence. Bonferroni correction for multiple testing was applied for post hoc testing.

For decision tree analysis, all volumetric measures were normalized by each subject\'s intracranial volume. Data were further processed by z‐transformation using mean centering and unit‐variance scaling of the sex‐ and age‐adjusted healthy control cohorts. *Z* scores ≥ ‐1.96 were omitted to prevent inclusion of insignificant cutoff values in the decision tree. A MRI‐based decision tree attempting to classify clinically diagnosed PD and MSA patients was developed exploiting the C4.5 classifier algorithm[29](#mds27669-bib-0029){ref-type="ref"}, [30](#mds27669-bib-0030){ref-type="ref"} implemented by the Waikato Environment of Knowledge Analysis machine learning software (WEKA 3.8.1). The following brain regions with potential discriminative value were considered: cerebellar white matter, cerebellar cortex, superior and middle cerebellar peduncle, putamen, caudate nucleus, pons, and midbrain. A 20‐fold cross‐validation was employed to estimate the classification performance of the decision tree.

Results {#mds27669-sec-0011}
=======

*Demographics and Basic Clinical Information* {#mds27669-sec-0012}
---------------------------------------------

Twenty‐six age‐matched healthy individuals, 31 MSA patients (18 MSA‐P, 13 MSA‐C), and 19 PD patients were included in the validation study. There was no significant difference between the study groups with regard to sex distribution (*P* = 0.882), age (*P* = 0.118), and disease duration (*P* = 0.787). Motor impairment was greater in MSA patients than in PD patients, as measured by Hoehn & Yahr staging (*P* \< 0.001) and the UPDRS (*P* \< 0.001). Detailed information on demographics and basic clinical information are provided in Table [1](#mds27669-tbl-0001){ref-type="table"}.

###### 

Demographics and basic clinical information

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                 HC sample        MSA          MSA‐P         MSA‐C          PD       *P* (post hoc tests[a](#mds27669-note-0002){ref-type="fn"})
  --------------------------------------------- ------------ ------------- ------------- ------------- ------------ -------------------------------------------------------------
  Sample size                                        26           31            18            13            19                                    ‐

  Age at scan (years), mean ± SD                 60.2 ± 5.9   61.8 ± 8.0    63.2 ± 7.0    59.7 ± 9.1    64.2 ± 5.3                              0.118

  Disease duration to scan (years), mean ± SD        ‐         2.6 ± 1.7     2.4 ± 1.8     2.8 ± 1.5    2.7 ± 1.4                               0.787

  Sex (female/male)                               11 / 15        14/17          9/9           5/8          7/12                                 0.882

  Hoehn & Yahr staging, median (IQR)                 ‐           3 (1)         3 (1)         3 (1)        2 (1)                               \<0.001\
                                                                                                                                        PD vs MSA‐P, \<0.001\
                                                                                                                                         PD vs MSA‐C, 0.005\
                                                                                                                                            MSA‐C, 0.844

  UPDRS III, mean ± SD                               ‐        38.8 ± 13.3   40.9 ± 7.0     35.8 ± 19    25.5 ± 6.7                            \<0.001\
                                                                                                                                        PD vs MSA‐P, \<0.001\
                                                                                                                                         PD vs MSA‐C, 0.041\
                                                                                                                                        MSA‐P vs MSA‐C, 0.659

  UPDRS sum score, mean ± SD                         ‐        62.0 ± 20.1   65.2 ± 10.5   57.6 ± 28.6   36.2 ± 9.8                            \<0.001\
                                                                                                                                        PD vs MSA‐P, \<0.001\
                                                                                                                                         PD vs MSA‐C, 0.003\
                                                                                                                                        MSA‐P vs MSA‐C, 0.675

  MMSE, mean ± SD                                    ‐        27.9 ± 2.2    28.2 ± 2.0    27.5 ± 2.4    29.0 ± 1.4                              0.104
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*P* values derived from group comparison between healthy controls (if applicable) and MSA‐P, MSA‐C, and PD patients. For post hoc testing Bonferroni correction for multiple testing was applied.

*Morphometric MR Profile of MSA Variants* {#mds27669-sec-0013}
-----------------------------------------

A detailed presentation of group differences is given in Table [2](#mds27669-tbl-0002){ref-type="table"}, and the frequency of atrophy of selected brain regions is presented in Table [3](#mds27669-tbl-0003){ref-type="table"}. In clinically classified MSA‐P patients putaminal and infratentorial atrophy were present in 77.8% and 61.1%, respectively. Isolated putaminal atrophy was seen in 38.8% of MSA‐P patients, whereas 22.2% showed isolated infratentorial atrophy without evidence of putaminal atrophy (Table [3](#mds27669-tbl-0003){ref-type="table"}, Fig. [1](#mds27669-fig-0001){ref-type="fig"}). Infratentorial atrophy was present in all MSA‐C patients, and 46.2% had concomitant putaminal atrophy. One PD patient (5.3%) who was clinically classified as having PD after 2 years of clinical follow‐up showed brain atrophy of the cerebellar white matter and the cerebellar cortex with volume reductions of more than 2 standard deviations compared with the mean of the sex‐ and age‐matched HC population. Automated brain volumetry of candidate brain regions was correlated with measures of disease severity (ie, UPDRS scores and Hoehn & Yahr staging; Supplementary [Table 1](#mds27669-supitem-0003){ref-type="supplementary-material"}). No correlation was found between disease duration and brain volumetry in candidate brain regions.

![Scatterplot of brain atrophy patterns in MSA‐P compared with MSA‐C and PD patients. Atrophy of the putamen and the most affected region among the olivo‐ponto‐cerebellar trajectory (ie, middle cerebellar peduncle, cerebellar white matter, cerebellar cortex, pons, labeled "infratentorial atrophy") are scattered to illustrate the predominant atrophy pattern in any individual patient. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](MDS-34-1041-g001){#mds27669-fig-0001}

###### 

Total intracranial volume‐corrected volumes of different brain regions

  ---------------------------------------------------------------------------------------------------------------------------------------
                                      HC             PD           MSA‐P          MSA‐C       *P* [a](#mds27669-note-0004){ref-type="fn"}
  ------------------------------ ------------- -------------- -------------- -------------- ---------------------------------------------
  Cerebellar white matter         9.71 ± 1.09   9.68 ± 1.24    8.28 ± 2.18    5.51 ± 1.26                     \<0.001\
                                                                                                          HC vs IPD, 1.000\
                                                                                                         HC vs MSA‐P, 0.015\
                                                                                                        HC vs MSA‐C, \<0.001\
                                                                                                         PD vs MSA‐P, 0.032\
                                                                                                        PD vs MSA‐C, \<0.001\
                                                                                                       MSA‐P vs MSA‐C, \<0.001

  Cerebellar cortex               36.78 ± 2.7   36.38 ± 2.78   33.38 ± 4.69   29.74 ± 2.38                    \<0.001\
                                                                                                          HC vs PD, 1.000\
                                                                                                         HC vs MSA‐P, 0.006\
                                                                                                        HC vs MSA‐C, \<0.001\
                                                                                                         PD vs MSA‐P, 0.039\
                                                                                                        PD vs MSA‐C, \<0.001\
                                                                                                        MSA‐P vs. MSA‐C 0.018

  Thalamus                        4.41 ± 0.27    4.52 ± 0.3    4.41 ± 0.31    4.30 ± 0.35                       0.257

  Caudate                         2.11 ± 0.24   2.14 ± 0.23     1.9 ± 0.32    2.11 ± 0.20                      0.019\
                                                                                                          HC vs PD, 1.000\
                                                                                                         HC vs MSA‐P, 0.048\
                                                                                                         HC vs MSA‐C, 1.000\
                                                                                                         PD vs MSA‐P, 0.034\
                                                                                                         PD vs MSA‐C, 1.000\
                                                                                                        MSA‐P vs MSA‐C, 0.138

  Putamen                         3.1 ± 0.23    3.06 ± 0.15    2.39 ± 0.43    2.72 ± 0.38                     \<0.001\
                                                                                                          HC vs PD, 1.000\
                                                                                                        HC vs MSA‐P, \<0.001\
                                                                                                         HC vs MSA‐C, 0.003\
                                                                                                        PD vs MSA‐P, \<0.001\
                                                                                                         PD vs MSA‐C, 0.015\
                                                                                                        MSA‐P vs MSA‐C, 0.025

  Hippocampus                     2.6 ± 0.29    2.69 ± 0.23    2.54 ± 0.32    2.62 ± 0.22                       0.453

  Amygdala                        0.97 ± 0.11   0.99 ± 0.09    0.96 ± 0.12    1.03 ± 0.10                       0.266

  Pons                             9.7 ± 0.8    9.85 ± 1.02    9.01 ± 1.65    6.23 ± 1.18                     \<0.001\
                                                                                                          HC vs IPD, 1.000\
                                                                                                         HC vs MSA‐P, 0.345\
                                                                                                        HC vs MSA‐C, \<0.001\
                                                                                                         PD vs MSA‐P, 0.182\
                                                                                                        PD vs MSA‐C, \<0.001\
                                                                                                       MSA‐P vs MSA‐C, \<0.001

  Midbrain                        3.94 ± 0.29   3.97 ± 0.29    3.86 ± 0.35    3.47 ± 0.23                     \<0.001\
                                                                                                          HC vs IPD, 1.000\
                                                                                                         HC vs MSA‐P, 1.000\
                                                                                                        HC vs MSA‐C, \<0.001\
                                                                                                          PD vs HC, 1.000\
                                                                                                         PD vs MSA‐P, 1.000\
                                                                                                        PD vs MSA‐C, \<0.001\
                                                                                                        MSA‐P vs MSA‐C, 0.003

  Superior cerebellar peduncle    0.84 ± 0.08   0.95 ± 0.14    0.87 ± 0.17    0.74 ± 0.14                     \<0.001\
                                                                                                          HC vs PD, 0.035\
                                                                                                         HC vs MSA‐P, 1.000\
                                                                                                         HC vs MSA‐C, 0.189\
                                                                                                         PD vs MSA‐P, 0.346\
                                                                                                        PD vs MSA‐C, \<0.001\
                                                                                                        MSA‐P vs MSA‐C, 0.058

  Middle cerebellar peduncle      6.56 ± 0.69   6.78 ± 0.86    5.75 ± 1.29    4.36 ± 0.70                     \<0.001\
                                                                                                          HC vs IPD, 1.000\
                                                                                                         HC vs MSA‐P, 0.027\
                                                                                                        HC vs MSA‐C, \<0.001\
                                                                                                         PD vs MSA‐P, 0.006\
                                                                                                        PD vs MSA‐C, \<0.001\
                                                                                                       MSA‐P vs MSA‐C, \<0.001
  ---------------------------------------------------------------------------------------------------------------------------------------

Values represent the ratio between the volume of the region divided by the subject‐specific total intracranial volume. In case of the bihemispheric presence of the region, the more affected side is presented. All numerical data are written as *m* × 10^‐3^.

*P* values derived from group comparison between healthy controls and MSA‐P, MSA‐C, and PD patients.

###### 

Frequency of z scores exceeding the 95% confidence interval of age‐ and sex‐matched healthy controls (ie, z score below −1.96) in selected regions

  Region                        MSA, overall     MSA‐P        MSA‐C         PD
  ---------------------------- -------------- ------------ ------------ ----------
  Cerebellar white matter        21 (67.7%)    8 (44.4%)    13 (100%)    1 (5.3%)
  Cerebellar cortex              19 (61.3%)    9 (50.0%)    10 (76.9%)   1 (5.3%)
  Middle cerebellar peduncle     18 (58.1%)    6 (33.3%)    12 (92.3%)   0 (0.0%)
  Putamen                        20 (64.5%)    14 (77.8%)   6 (46.2%)     0 (0%)
  Pons                           13 (41.9%)    2 (11.1%)    11 (84.6%)   0 (0.0%)
  Midbrain                        1 (3.2%)      0 (0.0%)     1 (7.7%)    0 (0.0%)

*Implications for the Differential Diagnosis of MSA Versus PD* {#mds27669-sec-0014}
--------------------------------------------------------------

Based on a C4.5 decision tree algorithm, atrophy measures of the putamen and the MCP were selected as the most useful parameters in differentiating MSA from PD. All PD patients and 93.5% of MSA patients (ie, sensitivity and specificity of 93.5% and 100%, respectively) were classified correctly (Fig. [2](#mds27669-fig-0002){ref-type="fig"}a). Cross‐validation of this model yields a weighted average *F* measure and a Cohen\'s kappa of 0.94 and 0.87, respectively. When the obtained cutoff values were exploited for the differential diagnosis of MSA‐P versus PD, a slightly lower sensitivity of 88.9% was observed while the specificity remained at 100% (overall correct classification, 94.6%). The algorithm unambiguously discriminated MSA‐C patients from PD patients with corresponding sensitivity and specificity rates of 100% each. The omission of the MCP volume resulted in a reduced weighted average *F* measure on cross‐validation of 0.90. In contrast, pooling of infratentorial atrophy measures (ie, selecting the most severely affected *Z* score of the MCP, cerebellar white matter, and cerebellar cortex) resulted in improved classification with 1 additional MSA patient being classified correctly (96.8% of MSA patients and all PD patients were classified correctly; Fig. [2](#mds27669-fig-0002){ref-type="fig"}b). Cross‐validation of this model yielded a weighted average *F* measure and Cohen\'s kappa of 0.94 and 0.87, respectively.

![Diagnostic algorithm. (a) Decision tree classifying MSA and PD based on single‐region measurements. (b, c) Decision tree classifying MSA and PD (lit. b) as well as MSA‐P and PD (lit. c) based on single‐region measurements and pooled infratentorial atrophy score (minimum *z* score of middle cerebellar peduncle, cerebellar white matter, and cerebellar cortex). \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](MDS-34-1041-g002){#mds27669-fig-0002}

Discussion {#mds27669-sec-0015}
==========

In the present study, probabilistic information on the relative location of the MCP was integrated into the currently available standard atlas of FreeSurfer‐based subcortical segmentation. Automated volumetry in MSA patients showed that both putaminal and infratentorial atrophy is present in both MSA variants (ie, MSA‐P and MSA‐C). Intriguingly, 22.2% of MSA‐P patients revealed isolated infratentorial atrophy without evidence of putaminal atrophy. Based on these findings, we were able to develop an automated MRI decision support algorithm that includes volumetric information of infratentorial (ie, volumetry of the MCP, cerebellar gray and white matter) and putaminal atrophy, and this approach proved to be superior compared with existing volumetric MRI processing strategies in differentiating patients with MSA from PD on an individual subject level.

Gross anatomy examinations commonly distinguish 2 major patterns of neurodegeneration in MSA---OPCA and SND. Clinicopathological studies found that 42% to 49% of MSA cases showed equally severe striatonigral degeneration and olivopontocerebellar atrophy, whereas atrophy patterns with either predominant SND or OPCA were evident in 34% and 17% of cases, respectively.[4](#mds27669-bib-0004){ref-type="ref"} In the present study, infratentorial atrophy was present in all MSA‐C patients and 61.1% of MSA‐P patients, whereas putaminal atrophy was found in 77.8% of MSA‐P patients and 46.2% of MSA‐C patients. In addition, 4 of 18 MSA‐P patients showed isolated infratentorial atrophy. Although the observed frequency of cerebellar white‐matter atrophy was in the range of that obtained by the MCP volumetry in the entire MSA cohort, among MSA patients with normal putaminal volume, MCP atrophy yielded the largest area under the receiver operating characteristics curve when comparing MCP, cerebellar white matter, and cerebellar cortex volume (Supplementary [Fig. 2](#mds27669-supitem-0002){ref-type="supplementary-material"}).

These observations suggest that both SND and OPCA atrophy patterns need to be scrutinized by including the MCP to the cerebellar and putaminal assessment to obtain a reliable imaging‐supported diagnosis of MSA.

Early quantitative MRI studies primarily focused on planimetric measurements of infratentorial brain regions, and these studies suggested that MSA is associated with relatively greater pontine and MCP atrophy compared with PSP and PD patients.[14](#mds27669-bib-0014){ref-type="ref"} The latter observations led to the development of 2‐dimensional planimetric measurements including the MCP width and the MR Parkinson index that were shown to support the differential diagnosis of neurodegenerative parkinsonian disorders.[10](#mds27669-bib-0010){ref-type="ref"}, [12](#mds27669-bib-0012){ref-type="ref"}, [31](#mds27669-bib-0031){ref-type="ref"}, [32](#mds27669-bib-0032){ref-type="ref"}, [33](#mds27669-bib-0033){ref-type="ref"}, [34](#mds27669-bib-0034){ref-type="ref"} Attempts to reduce visual inspection biases of manual measurement methods and the requirement to establish 3‐dimensional volume measurements gave rise to the development of automated, atlas‐based analysis tools. Such 3‐dimensional and automated imaging efforts improved diagnostic accuracy rates for the differential diagnosis of degenerative parkinsonian disorders in recent years. By applying a support vector machine to classify regional volumetric MRI data, a multicenter study achieved sensitivity ranging from 79% to 87% and specificity from 87% to 96% for the diagnosis of PD, PSP, and MSA (combining MSA‐P and MSA‐C into 1 group).[16](#mds27669-bib-0016){ref-type="ref"} Another approach used mean values of gray‐mater density, diffusion tensor, and r2\* signal within voxel‐clusters obtained from previous group analysis of patients with PD and MSA (including patients with MSA‐P and MSA‐C) and reported \>95% discrimination accuracy of fractional anisotropy clusters of the cerebellum, brain stem, and white‐matter bilateral superior corona radiate combined with another mean diffusivity cluster of the right superior frontal gyrus.[15](#mds27669-bib-0015){ref-type="ref"} In the present study, monomodal volumetric measurements were harmonized by *z* transformation to rank affected brain areas according to their volume loss in individual patients. Furthermore, in an attempt to avoid the inclusion of volumes from brain areas within the normal range into the diagnostic algorithm, only measurements that showed a reduction of more than 2 standard deviations from the mean of the healthy control sample were considered. Finally, the 3‐dimensionally measured volume of the MCP, a brain region known to be frequently affected in patients with MSA, was added to the list of assessed brain volumes. The diagnostic algorithm was then generated by means of a C4.5 decision tree algorithm. This hierarchical stepwise classifier identified the volume of the putamen and the MCP as the most discriminative parameters to separate PD and MSA. Diagnostic accuracy was further improved by the introduction of a pooled infratentorial atrophy measure that represents the most severely affected *z* score of the middle cerebellar peduncle, cerebellar white matter, and cerebellar cortex. Only 1 patient with a diagnosis of MSA was incorrectly assigned to the PD group. This patient already had a substantial infratentorial atrophy (*z* score, ‐2.1) at a very early disease stage (symptom duration, 1.25 years), which is highly suspicious for a diagnosis of MSA; however, in this proof‐of‐concept design, the classifier C4.5 selected a more stringent cutoff to improve specificity at the expense of sensitivity. In addition, the pooled infratentorial atrophy measure was superior to single parameters to classify patients with MSA‐P from PD. Cross‐validation suggested a good fit of the model to an independent data set. The current model also extends previous work following a similar approach by introducing more accurate characterization of infratentorial atrophy and by applying the automated morphometric analysis on MSA‐C patients.[19](#mds27669-bib-0019){ref-type="ref"}

The lack of postmortem confirmation is a potential limitation of the present study. However, we stringently applied validated clinical criteria, with consensus on the diagnosis from 2 experts in movement disorders being required. The final clinical classification was anchored on the last visit after an extended follow‐up period of at least 24 months. In addition, ancillary investigations including radiotracer imaging confirming nigrostriatal dopaminergic deficit and structural imaging excluding secondary causes were supportive of the degenerative nature of the movement disorder. The cross‐sectional design of the present study impedes a detailed characterization of the temporal evolution of MSA atrophy patterns; hence, future longitudinal MRI studies exploiting MRI volumetry should be performed in cases with early MSA to better characterize progression of brain atrophy over the course of the disease in MSA patients more precisely.

Despite the known benefits of decision tree algorithms like simplicity in constructing, robustness, and interpretability for clinicians, some potential limitations must also be considered. Decision trees often exhibit low diagnostic precision because of the strictly horizontal and vertical decision boundaries created by decision trees. Readers should also be aware that the decision trees, like any other statistical model, may change in structure if important variables are added or removed. Therefore, the decision trees should be viewed as descriptive explorative analysis explaining the data, but they are not confirming predictors.[35](#mds27669-bib-0035){ref-type="ref"}, [36](#mds27669-bib-0036){ref-type="ref"}

In summary, the inclusion of the MCP in the automatized morphometric analysis corroborates previous neuropathological studies that showed that most MSA patients have a mixed SND and OPCA pathology and that brain atrophy patterns do not necessarily correspond to the clinical impression of predominant motor deficits. The combination of automated subcortical and supra‐ and infratentorial segmentation that included the volumetric measure of the MCP further improved the existing volumetric MRI decision support strategies on the diagnostic accuracy in separating MSA from PD. This approach will improve appropriate patient counseling and recruitment of homogenous patient cohorts into clinical studies. In addition, a more detailed automated brain segmentation based on anatomical MR sequences will also facilitate future longitudinal as well as multimodal imaging approaches.
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**SUPPLEMENTARY FIG. 1** Three‐dimensional models of the middle cerebellar peduncles in a PD patient (a) and a MSA‐C patient (b).
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**SUPPLEMENTARY FIG. 2** Receiver operating characteristic curve analysis of relevant brain regions in MSA patients without putaminal atrophy.
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**SUPPLEMENTARY TABLE 1** Correlation between clinical scores and volumetric MR measures in MSA and PD patients

###### 

Click here for additional data file.

The newly developed FreeSurfer‐compatible atlas for automated subcortical segmentation will be shared with interested parties on formal request to the authors.
